Magnasense Management

Management Kriterienprüfungen 0/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Marco Wititteveen

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	1.1yrs
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	1.1yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	2.5yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Marco Wititteveen

1.1yrs

Amtszeit

Mr. Marco Wititteveen serves as Chief Executive Officer of Magnasense AB (formerly known as AegirBio AB (publ)) since June 15, 2023. He has previously had multiple different roles in Med Tech and diagnosti...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Bradley Messmer	Chief Scientific Officer & Member of the Board	no data	SEK 1.28m	1.39% SEK 224.7k
Marco Wititteveen	Chief Executive Officer	1.1yrs	keine Daten	keine Daten
Niklas Andersson	Chief Financial Officer	1.5yrs	keine Daten	keine Daten
Vasiliki Fragkou	Chief Operating Officer	less than a year	keine Daten	keine Daten

1.1yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: AEGIRDas Führungsteam des Unternehmens gilt nicht als erfahren ( 1 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Bradley Messmer	Chief Scientific Officer & Member of the Board	4.4yrs	SEK 1.28m	1.39% SEK 224.7k
Seppo Makinen	Independent Member of the Board	4.4yrs	SEK 168.00k	keine Daten
William Vickery	Independent Director	2.5yrs	keine Daten	keine Daten
Iain L. Chapple	Member of Scientific Advisory Board	less than a year	keine Daten	keine Daten
Sofia Bertling	Independent Director	2.5yrs	keine Daten	keine Daten
Fredrik Haglund	Independent Member of the Board	4.2yrs	SEK 48.00k	0.52% SEK 84.0k
Adam Cheifetz	Scientific Advisory Board	less than a year	keine Daten	keine Daten
Melissa Grant	Member of Scientific Advisory Board	no data	keine Daten	keine Daten

2.5yrs

Durchschnittliche Betriebszugehörigkeit

54yo

Durchschnittliches Alter

Erfahrener Vorstand: AEGIRDie Vorstandsmitglieder gelten nicht als erfahren ( 2.4 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.

Magnasense Management

Management Kriterienprüfungen 0/4

Wichtige Informationen

Jüngste Management Updates

AegirBio AB Appoints Melissa Grant to its Scientific Advisory Board

AegirBio AB (publ), Annual General Meeting, Jun 28, 2024

AegirBio AB (publ), Annual General Meeting, Jun 28, 2024

AegirBio AB (publ) Announces Intention of Anders Ingvarsson to Resign as Board Member and Chairman

AegirBio AB (Publ) Announces the Appointment of Iain L. C. Chapple to the Scientific Advisory Board

AegirBio AB (publ) Appoints Adam S. Cheifetz as Scientific Advisory Board

Recent updates

AegirBio AB Appoints Melissa Grant to its Scientific Advisory Board

AegirBio AB (publ), Annual General Meeting, Jun 28, 2024

AegirBio AB (publ), Annual General Meeting, Jun 28, 2024

First quarter 2024 earnings released: kr0.16 loss per share (vs kr0.64 loss in 1Q 2023)

New minor risk - Share price stability

AegirBio AB (publ) Announces Intention of Anders Ingvarsson to Resign as Board Member and Chairman

New major risk - Negative shareholders equity

Full year 2023 earnings released: kr2.38 loss per share (vs kr18.90 loss in FY 2022)

AegirBio AB (Publ) Announces the Appointment of Iain L. C. Chapple to the Scientific Advisory Board

New minor risk - Share price stability

AegirBio AB (publ) Appoints Adam S. Cheifetz as Scientific Advisory Board

Aegirbio AB Receives Phase 1 Award from the National Institutes of Health (Nih) Rapid Acceleration of Diagnostics (Radx®) Tech Program for an Accessibility Project for Multiplex Testing

AegirBio Announces Management Changes

Aegirbio AB (Publ) Announces CEO Changes

Independent Member of the Board exercised options to buy kr86k worth of stock.

AegirBio AB (publ) announced that it expects to receive SEK 55 million in funding from Atlas Special Opportunities LLC

High number of new and inexperienced directors

AegirBio Receives Approval from the Notified Body to Prolong the Shelf Life of Its Covid-19 Antigen Test

AegirBio Announces First Clinical Saliva TDM Study in US

High number of new and inexperienced directors

High number of new and inexperienced directors

AegirBio AB (publ) Receives Intention to Grant from the European Patent Office

New 90-day high: kr30.88

Aegirbio Announces the Addition of Brandon Steele to Their Senior Management Team as Chief Commercial Officer

AegirBio AB (publ) (OM:AEGIR) agreed to acquire LifeAssays AB (publ) (NGM:LIFE B)

New 90-day high: kr25.50

AegirBio AB (publ) Announces That the Direct Aid of Approximately SEK 4.3 Million or €419,500 Granted to Aegirbio AB’s Eurostar application

Aegirbio Commences FDA Fast Track Process with COVID-19 Test

Aegirbio Announces Convincing Results for Aegirbio's Coronavirus Test in Italian-Swedish Study

Aegirbio AB Signs A Research & Development Agreement with MediaPharma

AegirBio AB (publ) (OM:AEGIR) acquired Viraspec AB for SEK 10 million.

Geschäftsführer

Amtszeit

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter